Two-year results of intravitreal triamcinolone acetonide injection for the treatment of macular edema due to central retinal vein occlusion

Ann Ophthalmol (Skokie). 2007 Winter;39(4):307-12. doi: 10.1007/s12009-007-9016-x.

Abstract

We investigated intravitreal triamcinolone acetonide injection for the treatment of macular edema due to central retinal vein occlusion in 20 patients. Mean central macular thickness at 3 days, 1, 3, 6, 12, 18, and 24 months postoperatively was different than baseline. Visual acuity did not change. Intravitreal triamcinolone injection significantly improves short-term anatomy, but recurrences and steroid-related complications were noted in the longer term.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Glucocorticoids / administration & dosage*
  • Glucocorticoids / adverse effects
  • Glucocorticoids / therapeutic use
  • Humans
  • Injections
  • Intraocular Pressure / drug effects
  • Macular Edema / diagnosis
  • Macular Edema / drug therapy*
  • Macular Edema / physiopathology
  • Male
  • Middle Aged
  • Recurrence
  • Retinal Vein Occlusion / complications*
  • Tomography, Optical Coherence
  • Treatment Outcome
  • Triamcinolone Acetonide / administration & dosage*
  • Triamcinolone Acetonide / adverse effects
  • Triamcinolone Acetonide / therapeutic use
  • Visual Acuity / drug effects
  • Vitreous Body

Substances

  • Glucocorticoids
  • Triamcinolone Acetonide